PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK
Keyword(s):
The Uk
◽
2020 ◽
Vol 36
(9)
◽
pp. 1507-1517
2015 ◽
Vol 16
(13)
◽
pp. 1915-1927
◽
Keyword(s):
2018 ◽
Vol 34
(10)
◽
pp. 457-465
◽
Keyword(s):